Search
for
Sort by
Research 31–60 of 777
- Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis
- Possible Involvement of Skin‐Resident Memory T Cells in Refractory Chronic Alopecia Areata
- 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Advances in the mechanism and new therapies of alopecia areata
- Citrullination at the Inflammatory Skin Barrier
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- Emerging role of baricitinib in dermatology practice: All we need to know!
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Current and future pharmacotherapy for alopecia areata
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Alopecia areata treatment with baricitinib: different relapse phenotypes
- Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
- Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
- Alopecia Areata
- Ruxolitinib: A novel molecule in the management of dermatological disorders
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia